Original Article Exploring the Efficacy of Telmisartan and Cilnidipine Combination Therapy in Hypertension: A Cross-sectional Analysis
Telmisartan-Cilnidipine Combo in Hypertension
DOI:
https://doi.org/10.15713/ins.bhj.175Keywords:
Cilnidipine, Combination therapy, Diuretics, Hypertension, TelmisartanAbstract
Introduction: Hypertension is a common non-communicable disease and is of major public health concern accounting for
19% of all deaths globally. The lack of awareness about hypertension is a major contributory factor for the delayed diagnosis
of asymptomatic cases, thus being labeled as a “silent killer disease.” Effective control of blood pressure is a must and
for achieving it, a long-acting antihypertensive agent is required. Telmisartan is one of the angiotensin II receptor blockers
whereas cilnidipine is a novel calcium antagonist. Cilnidipine has shown prolonged and desirable antihypertensive effects. The
present questionnaire-based study conducted on various clinicians across different parts of the country analyses the pattern
of patients with hypertension and other comorbidities in their clinical practice along with the trend in the prescription of
antihypertensives either mono and/or combination therapy. Materials and Methods: The present study is a questionnairebased
cross-sectional study consisting of 25 validated structured questions. The study was approved by the Institutional
Ethical Committee. All the completed forms were included in the study whereas incomplete form was excluded from the
study. Observation and Results: The survey reflects that 87% of the patients have diabetes mellitus as one of the most
common comorbid conditions associated with hypertension. About 86.5% of the clinicians (86.5%) are of the opinion that
more than 30% of the patients required combination therapy of telmisartan and cilnidipine with the addition of diuretics in
uncontrolled hypertension. The combination also offers many other benefits such as its anti-atherosclerotic properties and endorgan
protection. Conclusion: The study highlights that combination therapy is very effective in treating hypertension even if
associated with other comorbid conditions such as diabetes and chronic kidney disease.
References
Communicable Diseases; 2021. Available from: https://www.who.
int/news-room/factsheets/detail/noncommunicable-diseases
[Last accessed on 2022 Oct 10].
Whelton PK, Carey RM, Aronow WS, Casey DE Jr., Collins KJ,
Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/
ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the
prevention, detection, evaluation, and management of high blood
pressure in adults: Executive summary: A report of the American
College of Cardiology/American Heart Association Task Force on
clinical practice guidelines. Hypertension 2018;71:1269-324.
World Health Organization (WHO). Fact Sheet on Hypertension;
Available from: https://www.who.int/news-room/factsheets/
detail/hypertension [Last accessed on 2022 Oct 10].
Dadlani A, Madan K, Sawhney JP. Ambulatory blood pressure
monitoring in clinical practice. Indian Heart J 2019;71:91-7.
Smith DH, Neutel JM, Lacourciere Y, Kempthorne Rawson J.
Prospective, randomized, open-label, blinded endpoint (PROBE)
designed trials yield the same results as double-blind, placebocontrolled
trials with respect to ABPM measurements. J Hypertens
;21:1291-8.
Konda T, Enomoto A, Aritomi S, Niinuma K, Koganei H, Ogawa T,
et al. Different effects of L/N-type and L-type calcium channel
blockers on the renin-angiotensin-aldosterone system in SHR/
Izm. Am J Nephrol 2009;30:155-61.
Sharma S. Hypertension therapeutics update: A brief clinical
summary of azilsartan, cilnidipine and nebivolol. Hypertens J
;1:111-7.
Ahmadi S, Sajjadi H, Nosrati Nejad F, Ahmadi N, Karimi SE,
Yoosefi M, et al. Lifestyle modification strategies for controlling
hypertension: How are these strategies recommended by
physicians in Iran? Med J Islam Repub Iran 2019;33:43-9.
Kapil U, Khandelwal R, Ramakrishnan L, Khenduja P, Gupta A,
Pandey RM, et al. Prevalence of hypertension, diabetes, and
associated risk factors among geriatric population living in a highaltitude
region of rural Uttarakhand, India. J Family Med Prim
Care 2018;7:1527-36.
Sawant R, Suryawanshi S, Jadhav M, Barkate H, Bhushan S, Rane T.
A prospective, randomized open-label study for assessment of
antihypertensive effect of telmisartan versus cilnidipine using
ambulatory blood pressure monitoring (START ABPM study).
Cardiol Res 2023;14:211-20.
Sofogianni A, Stalikas N, Antza C, Tziomalos K. Cardiovascular
risk prediction models and scores in the era of personalized
medicine. J Pers Med 2022;12:1180-90.
Kato H, Shiraishi T, Ueda S, Kubo E, Shima T, Nagura M, et al.
Blood pressure control and satisfaction of hypertensive patients
following a switch to combined drugs of an angiotensin receptor
blocker and a calcium channel blocker in clinical practice of
nephrology. Clin Exp Nephrol 2015;19:465-73.
Mori Y, Aritomi S, Niinuma K, Nakamura T, Matsuura K,
Yokoyama J, et al. Additive effects of cilnidipine, an L-/N-type
calcium channel blocker, and an angiotensin II receptor blocker on
reducing cardiorenal damage in Otsuka Long-Evans Tokushima
Fatty rats with type 2 diabetes mellitus. Drug Des Devel Ther
;8:799-810.
Kaneshiro Y, Ichihara A, Sakoda M, Kurauchi A, Takemitsu T,
Itoh H. Cilnidipine and telmisartan similarly improves vascular
damage in hypertensive patients. Clin Med Cardiol 2007;1:1-11.
Bekki H, Yamamoto K, Sone M, Homma T, Nakata M, Nohara M,
et al. Efficacy of combination therapy with telmisartan plus
amlodipine in patients with poorly controlled hypertension. Oxid
Med Cell Longev 2010;3:342-6.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Bombay Hospital Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
© The Author(s). 2024 Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons. org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and non-commercial reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/ zero/1.0/) applies to the data made available in this article, unless otherwise stated.
